Immune thrombocytopenia in adults: A single‐centre review of demographics, clinical features and treatment outcomes. (19th June 2020)

• Record Type: Journal Article
• Authors: Woolley, Philippa; Newton, Rosalind; Mc Guckin, Siobhan; Thomas, Mari; Westwood, John‐Paul; Scully, Marie A.
• Is Part Of: European journal of haematology. Volume 105:Number 3(2020)
• Page Start: 344
• Page End: 351
• Publication Date: 2020-06-19
• Subjects: coagulation disorders -- immunology and infectious diseases -- thrombocytes; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13456
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objectives: Primary immune thrombocytopenia (ITP) is a bleeding disorder characterised by an isolated thrombocytopenia in the absence of an alternative diagnosis. The condition is highly heterogeneous with some patients requiring multiple of therapy before achieving response. In this study, we collected data on a large cohort of primary ITP patients with the objective of identifying variables which may predict treatment requirements. Methods: We collected data on 379 patients, 275 with a confirmed diagnosis of primary ITP included demographics, baseline laboratory results and treatments. These were compared against treatment responses and lines of therapy. Results: Patients who presented with a platelet count of <30 × 10 9 /L or bleeding symptoms were observed to require more subsequent lines of therapy ( P ‐value <0.001). 32% of patients (n = 87) received no treatment, and these patients had a significantly higher median count compared to those with required >2 lines of therapy ( P ‐value <0.001). Superior response rates were demonstrated with thrombopoietin receptor agonists when compared with other agents irrespective of baseline characteristics. Conclusions: Platelet counts at diagnosis are a potentially strong predictive indicator of subsequent lines of therapy. Patients with bleeding symptoms at diagnosis were more likely to have lower median platelets counts.